Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label, Active-controlled, Parallel-group, Multi-center Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease.

NCT07300111 is registered in ClinicalTrials.gov with Qilu Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07300111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07300111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label, Active-controlled, Parallel-group, Multi-center Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease.
Lead sponsor
Qilu Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 31, 2025
Completion date
July 31, 2027
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anaemia